Australian scientists have discovered a new species of the deadly funnel-web spider that is bigger and more venomous than its relatives, nicknaming it "Big Boy." In research released Monday ...

A new species of Funnel Web Spider named Atrax christenseni and nicknamed ‘Big Boy’ is pictured at the Australian Museum in Sydney (Picture: Reuters) A new type of spider, nicknamed the ‘big ...

A larger and more venomous species of one of the world's deadliest spiders has been confirmed by Australian scientists. Nicknamed 'big boy', it can grow up to 9cm (3.54 inches) compared with 5cm ...

Ah, the scorpion lollipop, a symbol of the Sonoran Desert. I like them, if only for the campiness of the dark, goth-looking scorpion encased unhappily in a gentle green, pink or blue. That said, ...

Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...

Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan Healthcare Conference with a deal to buy Scorpion Therapeutics ...

We look forward to leveraging the great work of the Scorpion team to date, along with Lilly's deep expertise in breast cancer, to further advance STX-478 with speed and focus." Under the terms of ...

Eli Lilly has turned to a biotechnology startup for help building its pipeline of cancer drugs, agreeing on Monday to purchase an experimental cancer drug from privately held Scorpion Therapeutics for ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of ...

SAN FRANCISCO — Eli Lilly said Monday it would acquire a cancer program from startup Scorpion Therapeutics in a deal worth up to $2.5 billion, as the Indianapolis company broadens its pipeline.

Eli Lilly (NYSE:LLY) is in advanced discussions to purchase cancer-focused biotech Scorpion Therapeutics for as much as $2.5 billion. A deal is likely to be reached in the coming days ahead of the ...